Tyra Biosciences, Inc. TYRA FGFR Discovery — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tyra Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tyra Biosciences, Inc.'s fgfr discovery — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tyra Biosciences, Inc.'s FGFR discovery — research and development expense?
- Tyra Biosciences, Inc. (TYRA) reported FGFR discovery — research and development expense of $2.53M in Q1 2026.
- How has Tyra Biosciences, Inc.'s FGFR discovery — research and development expense changed year-over-year?
- Tyra Biosciences, Inc.'s FGFR discovery — research and development expense decreased by 19.2% year-over-year, from $3.13M to $2.53M.
- What is the long-term trend for Tyra Biosciences, Inc.'s FGFR discovery — research and development expense?
- Over 2 years (2023 to 2025), Tyra Biosciences, Inc.'s FGFR discovery — research and development expense has grown at a 41.3% compound annual growth rate (CAGR), from $5.49M to $10.97M.
- What does FGFR discovery — research and development expense mean?
- This metric represents the total operating expenses specifically allocated to research and development activities within the FGFR discovery segment. It captures the investment in scientific discovery, preclinical studies, and platform development aimed at identifying and advancing novel therapeutic candidates targeting FGFR biology. Tracking this expenditure provides insight into the company's commitment to innovation and the pace of its pipeline development within this core therapeutic focus area.